Policy Interpretation of the Implementation Opinion of the National Medical Products Administration on “AI + Drug Regulation”

The National Medical Products Administration issued the Implementation Opinion on “AI + Drug Regulation”, targeting the deep integration of artificial intelligence into drug oversight across the full product lifecycle. The focus is on building intelligent systems for review and approval, inspection, risk monitoring, and government services, with a goal of establishing a fully AI-driven smart drug safety governance framework by 2035.​​​​​​​​​